Pembrolizumab for Fanconi anemia with advanced tongue cancer

With underlying Fanconi Anemia, head and neck cancer treatment options are usually limited due to the chromosome instability. Pembrolizumab plays a vital role in head and neck cancer with recurrence and distant metastases. However, the safety of pembrolizumab for Fanconi anemia patients has not been...

Full description

Saved in:
Bibliographic Details
Published in:Otolaryngology case reports 2022-06, Vol.23, p.100430, Article 100430
Main Authors: Nagano, Keitaro, Osaki, Masami, Hatanaka, Akio, Kinoshita, Shingo
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With underlying Fanconi Anemia, head and neck cancer treatment options are usually limited due to the chromosome instability. Pembrolizumab plays a vital role in head and neck cancer with recurrence and distant metastases. However, the safety of pembrolizumab for Fanconi anemia patients has not been investigated well. We present the case of an 18-year-old female with advanced tongue cancer caused by Fanconi anemia. Considering the chromosome instability, she was initially on pembrolizumab alone before switching to cetuximab, and pembrolizumab was generally well tolerated. We considered pembrolizumab a suitable treatment option for Fanconi Anemia, despite the possibility of her grade 3 colitis (irAE) being aggravated by the Fanconi anemia related chromosome instability.
ISSN:2468-5488
2468-5488
DOI:10.1016/j.xocr.2022.100430